Minerva Neurosciences, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of proprietary product candidates for central nervous system diseases. The company's lead candidate is roluperidone which is being developed to treat negative symptoms in patients diagnosed with schizophrenia. Minerva Neurosciences, Inc. also previously co developed seltorexant for insomnia and major depressive disorder before selling its royalty rights to Royalty Pharma. The firm was formed in November 2013 through the merger of Cyrenaic Pharmaceuticals, Inc. and Sonkei Pharmaceuticals, Inc. Its headquarters are located in Burlington Massachusetts and it trades on the Nasdaq Capital Market under the ticker NERV.

The company has not generated any revenue from the sales or license of its product candidates to date. In January 2021 Minerva Neurosciences, Inc. sold its rights to future royalties from seltorexant to Royalty Pharma for an upfront cash payment of sixty million dollars and the potential to receive up to ninety five million dollars in milestone payments contingent on Janssen's progress with seltorexant. Until any product receives regulatory approval the company's revenue will depend on such milestone payments and any future financing activities. Minerva Neurosciences, Inc. has incurred significant operating losses since inception and expects to continue to incur net losses and negative cash flows from operating activities for the foreseeable future. As of December 31 2025 the company reported an accumulated deficit of six hundred eighty eight point eight million dollars.

Minerva Neurosciences, Inc. occupies a niche in the schizophrenia treatment landscape by focusing on negative symptoms which currently lack an approved pharmacologic therapy in the United States. Most existing antipsychotic medications target positive symptoms and are associated with side effects such as weight gain and sedation. Competing approaches in clinical development include agents targeting glutamate or nicotine pathways and muscarinic receptor modulators such as Cobenfy which has shown benefit for both positive and negative symptoms but has faced regulatory scrutiny over its marketing claims. The company differentiates itself through the unique mechanism of roluperidone which combines serotonin sigma and alpha adrenergic receptor blockade to potentially improve negative symptoms cognition and sleep without the metabolic liabilities of typical antipsychotics. In addition Minerva Neurosciences, Inc. holds a broad patent portfolio covering compositions methods of use and formulations of roluperidone with exclusivity extending into the mid 2030s providing a barrier to generic entry. The company's clinical data from two Phase 2b and Phase 3 trials show statistically significant improvement in negative symptom scales supporting its potential to address an unmet need. Roluperidone has been evaluated in monotherapy and in combination with antipsychotics to assess safety and efficacy under conditions that reflect real world prescribing patterns. Beyond schizophrenia the company is exploring the use of roluperidone in other central nervous system disorders where negative symptoms are a core feature such as apathy in dementia Alzheimer's disease Parkinson's disease and major depressive disorder. The firm's strategy emphasizes scientific rigor patient safety and engagement with investigators and caregivers to advance its product candidates through regulatory review.

Since Minerva Neurosciences, Inc. has not yet commercialized any product it does not have an active customer base. The company anticipates that upon approval its primary customers will include patients diagnosed with schizophrenia who experience negative symptoms and the healthcare providers who treat them such as psychiatrists psychiatric hospitals and outpatient mental health clinics. Additionally payors including government health programs and private insurers will be important stakeholders for reimbursement and access. The company also expects to engage with caregivers and patient advocacy groups to understand the burden of illness and to support treatment adherence. Commercialization efforts if successful would likely focus initially on the United States and select European markets where the prevalence of schizophrenia is high and unmet need for negative symptom therapy is recognized.